Herpes simplex virus type 2: Completed Phase I/II enrollment

Vical completed enrollment of 165 otherwise healthy HSV-2-infected patients ages 18-50 in a double-blind, placebo-controlled, U.S. Phase I/II trial evaluating its Vaxfectin-formulated plasmid DNA HSV-...